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SUMMARY
 
Our aim was to determine the pattern of expression of MUC1 mucin cytoplas-
mic tail (MUC1 CT) in breast carcinoma. A total of 98 invasive breast adenocarcinoma tu-
mor samples were assayed by immunohistochemical (IHC) analysis. The pattern of reaction
was classified as membrane, cytoplasmic, or mixed. Subcellular fractions were prepared af-
ter SDS-PAGE and Western blotting. The antibodies employed were anti-MUC1 CT (CT2
monoclonal antibody, MAb) and C595 MAb against the extracellular MUC1 core protein.
With the CT2 MAb, IHC showed a high percentage of positive staining in 93% of speci-
mens, with membrane staining the most common pattern observed. C595 MAb was reac-
tive in 73% of specimens. Similar percentages of membrane and cytoplasmic staining were
found, mainly in a mixed pattern. Western blotting showed different bands. With the CT2
MAb, the membrane fraction showed the most intense reaction; a strong band of reaction
was detected at approximately 
 
,
 
30 kD. With the C595 MAb, in most cases a double band
at 200 kD was found. In breast epithelium, the pattern of MUC1 CT expression may consti-
tute an indicator of MUC1 production because it does not depend on glycosylation. The
pattern and extension of MUC1 CT positivity do not vary according to the histopathological
subtype of the tumor.
 
(J Histochem Cytochem 51:781–788, 2003)
 
I
 
mmunohistochemical studies
 
 have indicated that
MUC1 mucin is widely expressed by breast epithelium
and that some of its changes have been associated
with malignant transformation. MUC1 is expressed
on the apical borders of normal secretory mammary
epithelial cells, whereas carcinoma counterparts ex-
hibit increased expression with different patterns, mainly
over the entire surface (Kufe et al. 1984; Patton et al.
1995; Croce et al. 1997; Rahn et al. 2001).
MUC1 exists in a heterodimeric form with a large
extracellular domain consisting predominantly of
variable numbers of O-glycosylated 20-amino-acid
tandem repeat peptides (VNTR) (mucin domain)
bound via noncovalent forces (Ligtenberg et al. 1992)
with a membrane-associated subunit. It consists of an
extracellular stem with a cleavage site, a transmem-
brane domain, and a 72-amino-acid cytoplasmic tail
(CT) (Gendler et al. 1990, 1998). Gendler (2001) has
speculated that this heterodimeric presentation of
MUC1 may provide a mechanism for rapid shedding
of the mucin domain. Soluble forms include the
ectodomain of full-length MUC1, termed MUC1/REP,
and a secreted form resulting from an alternative splic-
ing event, MUC1/SEC (Wreschner et al. 1990; Smoro-
dinsky et al. 1996). Additional cell-associated forms
have been detected in malignant cells, MUC1/Y (Zri-
han–Licht et al. 1994; Hartmann et al. 1999) and
MUC1/Z (Oosterkamp et al. 1997), which lack the
tandem repeats.
MUC1 has been involved in cell–cell (Wesseling et
al. 1995) and cell–matrix interactions (Regimbald et
al. 1996; Kam et al. 1998). It has also been observed
that MUC1 CT interacts with 
 
b
 
-catenin through a
similar motif to that found in E-cadherin and inhibits
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the formation of an E-cadherin–
 
b
 
-catenin complex,
reducing cell–cell adhesion (Yamamoto et al. 1997).
On the other hand, MUC1 has been associated with
putative signaling functions through motifs in the CT
(Li et al. 1998) because it contains potential docking
sites for SH2-including proteins as well as a variety of
possible kinase recognition sites (Spicer et al. 1995). In
MCF-7 breast carcinoma cells, Pandey et al. (1995)
demonstrated that on phosphorylation, MUC1 can
bind Grb2/SOS, signaling mediator of a number of ty-
rosine kinase receptors. Recent data obtained by
Schroeder et al. (2001) demonstrated that MUC1 co-
localizes and physically interacts with members of the
erbB receptor kinase family. Furthermore, EGF-depen-
dent activation of ERK1/2 is strongly induced in the
presence of high levels of MUC1 in the mouse mam-
mary gland, suggesting that MUC1 potentiates the sig-
naling of erbB family members, proteins whose in-
creased expression is correlated with aggressive breast
cancer (Wesseling et al. 1995).
The transmembrane and cytoplasmic domains of
MUC1 are conserved among mammalian species with
an amino acid identity of 80–90% (Pemberton et al.
1992). These authors suggested that this domain is
functionally important in the MUC1 molecule as a
whole. MUC1 has been shown to be recycled through
the 
 
trans
 
-Golgi network from the apical surface sev-
eral times (Litvinov and Hilkens 1993). It has also
been shown that the cytoplasmic tail may be involved
in endocytosis (Pemberton et al. 1996).
Immunohistochemical (IHC) MUC1 detection stud-
ies have included diverse anti-MUC1 monoclonal
antibodies (MAbs) against the extracellular domain,
mainly against different sequences from the VNTR
(Griffiths et al. 1987; Croce et al. 1997; Luna–Moré et
al. 2001; Rahn et al. 2001) and also against the carbo-
hydrate side chains (Renkonen et al. 1997; Nakagoe et
al. 2002). The present study was developed to find ev-
idence about MUC1 pattern expression in breast car-
cinoma by use of an anti-MUC1 CT MAb, because it
is a reliable indicator of the abundance of cell-associ-
ated MUC1 mucin.
 
Materials and Methods
 
Tissue Specimens
 
A total of 98 pretreatment tumor samples were obtained
from newly diagnosed breast cancer patients at different
stages of disease; all cases were typed as invasive adenocarci-
noma: not otherwise specified ductal type (NOS ductal) 56
(57%), papillary ductal carcinoma in situ (DCIS) with inva-
sive component 8 (8%), lobular type (LC) 30 (31%). Four
cases (4%) were medullary (MC). Disease staging was also
established: 23 (23%) corresponded to stage I, 45 (46%) to
stage II, 25 (25.5%) to stage III, and 5 (5%) to stage IV (Ta-
ble 1). Tumors corresponding to NOS ductal type showed
different grades of differentiation as follows: 7/56 (12%)
were well differentiated, 11/56 (20%) moderately differenti-
ated, and 38/56 (68%) were poorly differentiated tumors.
Mean age was 56 with a range of 25–86 years. The popula-
tion under study included non-smoking women.
Tissue samples from normal biopsy samples (
 
n
 
5
 
7) ob-
tained during breast cosmetic surgery as well as samples from
six patients with benign breast disease (cystic changes, adeno-
sis, and atypical hyperplasia) were also included as controls.
Procedures followed were in accordance with the Hel-
sinki Declaration. Informed consent was obtained from all
women included in this study.
Each tissue was studied using routine procedures. Speci-
mens were sectioned in several parts to cover different pro-
grammed studies. A piece of tissue was fixed for histo-
pathological diagnosis and IHC analysis. Another tissue
sample was rinsed with sterile Hank’s balanced solution
and processed for preparation of subcellular fractions (see
below).
 
Antibodies
 
Two monoclonal antibodies were assayed: MAb CT2, devel-
oped in Armenian hamster, directed against the last 17
amino-acids (SSLSYNTPAVAATSANL) of the cytoplasmic
tail of MUC1 (Schroeder et al. 2001), and MAb C595 devel-
oped against the VNTR from MUC1 core protein, which de-
fines the tetrameric epitope Arg-Pro-Ala-Pro (RPAP) in the
protein core (Price et al. 1990).
 
Methods
 
IHC Analysis.
 
The technique was performed according to
standard procedures. The specimens were fixed in Metha-
 
Table 1
 
 Pattern of immunohistochemical expression of breast carcinoma samples (%)
 
Tumor type
Positive/Total Membrane Cytoplasmic Mixed Negative/Total
CT2 C595 CT2 C595 CT2 C595 CT2 C595 CT2 C595
NOS ductal 52/56 39/56 23/52 8/39 9/52 6/39 23/52 25/39 4/56 17/56
(93) (70) (44.2) (20.5) (17.3) (15.5) (44.2) (64) (7) (30)
Papillary 8/8 7/8 6/8 2/7 0/8 0/7 2/8 5/7 0/8 1/8
(100) (87.5) (75) (29) (0) (0) (25) (71) (0) (12.5)
Lobular 28/30 24/30 4/28 2/24 6/28 7/24 18/28 15/24 2/30 6/30
(93) (80) (14) (8.5) (21) (29) (64) (62.5) (7) (20)
Medullary 3/4 2/4 0/3 1/2 1/3 1/2 2/3 0/2 1/4 2/4
(75) (50) (0) (50) (33) (50) (66) (0) (25) (50)
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carn (chloroform:methanol:acetic acid 60:30:10) for 2 hr and
then transferred into 70% ethanol until processing in paraf-
fin. Tissues were treated with 10 mM sodium citrate buffer
at 100C for 5 min and incubated overnight at 4C with either
CT2 or C595. In the first case, MAb CT2 diluted 1:500 was
employed. After three washes with phosphate buffer, biotin–
SP-conjugated affinity-purified goat anti-Armenian hamster
IgG (H
 
1
 
L) (Jackson ImmunoResearch; West Grove, PA) di-
luted 1:1000 was added and incubated for 1 hr. A final incu-
bation with peroxidase-conjugated streptavidin (Jackson Im-
munoResearch) was performed. MAb C595 diluted 1:1000
was used. After three washes with phosphate buffer, peroxi-
dase-conjugated goat anti-mouse IgG (Dakopatts; Copen-
hagen, Denmark) diluted 1:400 was added and incubated
for 60 min. The slides were counterstained with hematoxy-
lin and coverslipped with mounting medium.
Negative controls were incubated with PBS instead of
MAbs. Staining of cytoplasm and of plasma and nuclear
membranes was evaluated. Cells were considered positive
when at least one of these components was stained.
Sections were examined by light microscopy and the anti-
body staining patterns were scored in a semiquantitative
manner. Staining intensity was graded as negative (
 
2
 
), low
(
 
1
 
), moderate (
 
11
 
), or strong (
 
111
 
) (Feickert et al. 1990).
The number of low power (
 
3
 
10) optical fields in a specimen
that were positively stained was expressed as a percentage of
the total number of optical fields containing tissue.
The pattern of reaction was classified according to other
authors (Renkonen et al. 1997): membrane, cytoplasmic, or
mixed pattern (cytoplasmic mixed with plasma membrane
staining), and the positive reaction of the lumen content was
identified as cell debris or secretion.
 
Preparation of Subcellular Fractions.
 
Fractions were pre-
pared from all breast tissues according to Price et al. (1985).
Samples were exhaustively dissected, necrotic areas were dis-
carded, and neoplastic or normal tissues were cut into 1-mm
pieces and extensively washed with 10 mM Tris, pH 7.2.
Immediately thereafter, homogenization was performed in
an ice bath employing the same buffer with 0.01 M poly-
methylsulfonylfluoride (Sigma–Aldrich; St Louis, MO). Ho-
mogenates were filtered through a metallic mesh and centri-
fuged at 600 
 
3
 
 g at 4C for 30 min. The pellet obtained was
called the pellet/nuclear fraction. Supernatants were centri-
fuged at 105,000 
 
3
 
 g at 4C for 60 min. Precipitates were re-
suspended in 1.41 M PBS and called the membrane fraction;
supernatants corresponded to the cytoplasmic fraction.
Pellets, membrane as well as cytoplasmic fractions, were
dialyzed against 1.41 M PBS at 4C for 48 hr, lyophilized,
and stored at 
 
2
 
20C. Samples were then analyzed by SDS-
PAGE and immunoblotting.
 
SDS-PAGE and Immunoblotting.
 
The isolated fractions
were analyzed under reducing conditions in SDS-PAGE in a
discontinuous buffer system according to Laemmli (1980).
Fractions were resuspended in SDS-PAGE sample buffer
containing 2% SDS and 5% 2-mercaptoethanol and heated
at 90C for 5 min. After electrophoresis, gels were either
stained with Coomassie brilliant blue (Sigma–Aldrich) or
they were transferred electrophoretically to nitrocellulose
membranes (Towbin et al. 1979), which were blocked with
10 mM Tris-HCl (pH 7.4)/1% BSA (blocking buffer),
 
washed with saline 10 mM Tris-HCl (pH 7.4), and incu-
bated with MAb CT2 or C595 in blocking buffer. Primary
MAb CT2 was used at 1:500 and C595 at 1:800 in blocking
buffer. After an overnight incubation at 4C, the blots were
rinsed three times for 5 min in saline 10 mM Tris-HCl (pH
7.4) buffer. For blots incubated with MAb CT2, biotin–SP-
conjugated affinity-purified goat anti-Armenian hamster IgG
(H
 
1
 
L) (Jackson ImmunoResearch) diluted 1:10,000 in sa-
line 10 mM Tris-HCl was added, incubated for 1 hr, and
washed with the same buffer. A final incubation with perox-
idase-conjugated streptavidin (Jackson ImmunoResearch)
was performed according to the manufacturer’s instructions.
When MAb C595 was used as second antibody, peroxi-
dase-conjugated goat anti-mouse IgG (Dakopatts) diluted
1:800 was added. Nitrocellulose sheets were developed with
3,3
 
9
 
-diaminodiazobenzidine in 10 mM Tris-HCl (pH 7.4)
containing 1 
 
m
 
g/ml 30% H
 
2
 
O
 
2
 
.
 
Statistical Analysis
 
Statistical study was performed employing different meth-
ods. A multivariate analysis was applied through principal
component analysis (PCA) with Kendall correlation includ-
ing all standardized data. Relationship among variables
(metric and non-metric) was studied; a set of dichotomous
variables (dummy) was used to represent each non-metric
variable. Spearman rank correlation (
 
p
 
,
 
0.05) was also run,
including MUC1 detection through MAb CT2 and MAb
C595 and disease stage, histological type, and histological
grade. Comparison of percentage of positivity among groups
was studied using 
 
x
 
2
 
 analysis.
 
Results
 
Immunohistochemical Staining
 
Breast Carcinoma.
 
Employing MAb CT2, IHC anal-
ysis showed a high percentage of positive staining in
91/98 (93%) specimens. In 60/91 (66%) positive sam-
ples, the reaction comprised the entire specimen, while
in 31/91 (34%) staining was restricted to a few areas
of the sample. In most cases (82/91; 90%) the staining
intensity was strong (
 
111
 
).
Table 1 summarizes the percentage of positive re-
sults as well as the pattern of reaction according to the
tumor type.
In NOS ductal carcinoma, considerable heterogene-
ity of staining at the cellular localization was found. In
44.2% of specimens, only plasma membranes reacted
positively. Several tumors showed a continuous reac-
tion, whereas others showed a discontinuous pattern.
In several samples, luminal content was also stained.
Frequently, cytoplasmic staining was observed to-
gether with a membrane reaction in a mixed pattern
(Figures 1A and 1B). In 17.3% of specimens, the reac-
tion was restricted to the cytoplasm, either in a homo-
geneous pattern (Figure 1C) or with a granular aspect.
A high percentage of LC (64%) was stained both in
plasma membrane and in cytoplasm, with a mixed
pattern (Figure 1D). In 6/28 specimens, reaction com-
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prised only the cytoplasm, while staining restricted to
plasma membrane was found in a few samples.
All papillary DCIS with an invasive component ex-
amined showed a positive reaction, mainly at the
plasma membrane. Usually the reaction covered the
papilla externally and internally lined the apical mem-
brane (Figure 1E). Two specimens were also reactive
at the cytoplasmic level (mixed pattern).
Cytoplasmic staining was predominant or exclusive
in MC samples. As was expected, given that 93% of
tumors were reactive, no statistically significant corre-
lation was obtained among tumor stage, degree of dif-
ferentiation, or histopathological tumor type and
MUC1-CT expression detected with MAb CT2.
Immunohistochemical analysis was also performed
employing an anti-MUC1 VNTR MAb (MAb C595).
Intensity of reaction observed was as follows: 19/72
(26%) malignant samples showed strong intensity; 32/
72 (44%) showed moderate staining; 21/72 (29%)
showed low intensity, and 16/72 (22%) were negative.
Percentages of subcellular localization of MUC1 re-
activity related to tumor type are summarized in Table
1. Similar percentages of membrane and cytoplasmic
staining were found, mainly in a mixed pattern.
Statistical analysis did not show any correlation be-
 
tween MUC1 detection and disease stage, histological
type, or histological grade. Multivariate analysis by
PCA with Kendall correlation showed a significant
correlation between MAb CT2 and C595 staining
(
 
t5
 
0.5147).
 
Control Samples.
 
With the anti-cytoplasmic tail MAb
(MAb CT2) all control specimens showed positive re-
activity. MUC1 expression in samples of benign breast
disease and normal tissues was similar. Some speci-
mens showed a reaction restricted to a few areas, but
others showed more extensive staining. The pattern of
reaction was observed mainly at the apical level of
plasma membranes (Figure 1F), although several sam-
ples also showed a cytoplasmic apical reaction.
With MAb C595, benign breast samples showed
MUC1 tissue expression in two of six samples, while
three of seven normal specimens were reactive. The
staining pattern was mainly restricted to the apical
plasma membrane.
 
Subcellular Fractions
 
All tissue samples were subjected to subcellular frac-
tionation followed by SDS-PAGE and Western blot-
ting analysis of their derived fractions. In malignant
Figure 1 Immunohistochemical find-
ings obtained by incubation with
MAb CT2. (A) Breast carcinoma sec-
tion from NOS ductal type in which a
continuous linear reaction is observed
in two well-formed tubular struc-
tures. Some cells show a granular re-
action adjacent to the nuclear mem-
brane. (B) Tumor section from a NOS
ductal carcinoma. A granular pattern
staining is observed throughout the
cytoplasm and discontinuously in the
plasma membrane. (C) Tissue section
from a NOS ductal carcinoma. Positive
staining under a pure cytoplasmic dis-
continuous granular pattern is de-
picted. Inflammatory reaction is ob-
served in two parts of the picture. (D)
Lobular carcinoma tissue section
shows malignant cells in cords with
discontinuous positive staining at the
cell membrane and granular staining
throughout the cytoplasm. (E) Papil-
lary breast carcinoma showing a posi-
tive thick reaction under a linear pat-
tern restricted to the papillary apical
surface. (F) Atypical dysplasia tissue
section with a positive reaction at the
apical membrane. Original magnifica-
tions 3630.
 MUC1 Cytoplasmic Tail Expression in Breast Cancer
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tissue fractions, this analysis demonstrated the pres-
ence of several bands at different molecular weights
(MW). With MAb CT2, the fraction showing the most
intense reaction was the membrane moiety. Under de-
natured conditions, a smear reaction was usually ob-
tained from 20 kD up to 
 
,
 
200 kD, although some
bands were impossible to identify. An example is
shown in Figure 2A, where a strong band of reaction
was found at approximately 
 
,
 
30 kD and other minor
bands were found at 60 kD. The cytoplasmic and nu-
clear fractions showed the same reaction, with a mi-
nor intensity of staining. In some other samples, the
reaction at 
 
,
 
30 kD was split into two different bands
(data not shown).
The incubation with MAb C595 showed a double
band of reaction at approximately 180–200 kD in all
malignant tissue-derived fractions (Figure 2B). In one
third of samples, bands of MW 
 
.
 
200 kD were also
found in pellet, membrane, and cytoplasmic fractions.
A smear reaction from 
 
.
 
50 kD up to 
 
.
 
200 kD was
frequently observed in all fractions. In pellet fractions,
some samples (32%) showed additional bands at 70,
60, and 50 kD. In 29% of membrane fractions, bands
of about 100, 70, 60, 50, 40, and 25 kD were found.
Finally, in 50% of cytoplasmic fractions, bands of 80,
70, 60, 50, 40, 25 kD were observed.
 
Control Samples
 
By employing MAb CT2, pellet, membrane, and cy-
toplasmic fractions belonging to control samples showed
bands at 30 kD and also at about 60 kD. In some sam-
ples, a double band at 
 
.
 
180 kD, corresponding to
membrane fractions, was identified.
With MAb C595, a double band at 180 kD was
found in all fractions. A smear reaction from 50–60
kD up to 
 
.
 
200 kD was frequently observed in pellet,
nuclear, and membrane fractions. In pellet fractions
derived from three normal and two benign breast dis-
ease samples, bands at 70 kD and at 80 kD were also
found.
 
Discussion
 
To our knowledge, this is the first extended IHC study
developed in mammary gland tissues by employing an
anti-MUC1 CT MAb (MAb CT2). Results were com-
pared with an MUC1 tandem reactive MAb (MAb
C595) which may place our findings in the context
with the previously published literature. In breast can-
cer, MAb CT2 reacted with 93% of samples, and
MAb C595 stained 73.5%. All benign and normal
samples were reactive with CT2 but C595 failed to re-
act with some control specimens.
Breast carcinoma tumors are frequently reactive
with anti-VNTR MUC1 MAbs. Differences in per-
centages of reactive tumors depend on the MAb em-
ployed (Taylor–Papadimitriou et al. 1999). In recent
investigations on breast cancer tissue samples (Croce
et al. unpublished), we studied MUC1 expression em-
ploying three anti-MUC1-VNTR, C595, HMFG2,
and SM3 MAbs. Through this IHC approach, per-
centage of reactivity was 74%, 70%, and 47%, re-
spectively, lower than positive results obtained with
MAb CT2 in the present study.
MAb C595 binds the RPAP sequence (Price et al.
1990). The trimer DTR is recognized by different
MAbs (Petrakou et al. 1998) such as MAb HMFG2
(Burchell et al. 1989). In the study by Rahn et al.
(2001), all breast tumor specimens expressed MUC1
(71 in situ and invasive ductal, lobular, and ductal–
lobular admixed carcinomas), as well as adjacent re-
gions of normal glandular tissue. Their findings may
be explained by the fact that they used MAb B27.29,
which targets PDTRPAP (Blockzjil et al. 1998) and
which includes all the amino acids recognized by
MAbs C595 and HMFG2. Carbohydrate side chains
may also play a role because it is known that reactivity
of MAbs C595 (Spencer et al. 1999), HMFG2 (Bur-
chell and Taylor–Papadimitriou 1993), and B27.29
(Grinstead et al. 2002) are influenced by glycosyla-
tion.
On the other hand, MAb SM3 (Burchell et al.
1987) is considered the most cancer-specific MAb be-
cause it reacts mainly with malignant cells, whereas
low staining is observed in normal samples (Croce et
al. 1997; Taylor–Papadimitriou et al. 1999). MAb SM3
binds the pentapeptide PDTRP and the glycopen-
Figure 2 Western blot of extranuclear membranes belonging to
breast cancer samples. n, nuclear fraction; m, membrane fraction;
c, cytoplasmic fraction. Standard molecular weights are indicated
at left. (A) A smear reaction was obtained using MAb CT2, showing
some major bands at approximately ,30 kD. (B) A double band at
approximately 200 kD is identified, mainly in the membrane frac-
tion, after incubation with MAb C595.
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tapeptide PDT(
 
O
 
-alpha-d-GalNAc)RP; these epitopes
are recognized when the mucin is under-glycosylated
(Burchell et al. 1989; Möller et al. 2002).
Different authors (reviewed by Rahn et al. 2001)
have found contradictory results about MUC1 expres-
sion detected with anti-VNTR MUC1 MAbs in rela-
tion to different parameters such as prognosis, histo-
logical grade, response to treatment, estrogen and
progesterone receptors, and disease dissemination. We
are unable to comment on survival because of the very
short follow-up of our patients, but through a multi-
variate statistical analysis we did not find a significant
correlation among MUC1 expression and disease
stage, histological type, and histological grade.
With respect to subcellular localization of MUC1,
we have performed a detailed study of samples. In
breast cancer, MAb CT2 showed reactivity mainly at
the plasma membrane. The cytoplasmic staining was
more frequently found in a mixed pattern. MAb C595
showed a similar percentage of cytoplasmic and mem-
brane staining, mainly in a mixed pattern. Most sam-
ples did not show any polarization of the reaction
which, on the other hand, constituted the hallmark of
normal and benign tissue sample staining. In 330
breast carcinomas, Luna–Moré et al. (2001) have
found that a linear (membrane) pattern was the least
node-metastasizing, while the negative pattern was the
most with the exception of micropapillary carcino-
mas. Rahn et al. (2001) have pointed out that an ex-
tended expression of MUC1 in cancer cells correlates
with a better prognosis, although expression at the
apical level is an accurate indicator of functional dif-
ferentiation. In this sense, a correct localization is
probably crucial for normal function. Pemberton et al.
(1996) found that apical localization of MUC1 is con-
ferred by a motif in the extracellular domain and is re-
ported to require a CQC motif at the junction of the
cytoplasmic and transmembrane domains. Deletions
of the cytoplasmic tail of MUC1 have no effect on the
apical localization, and MUC1 without a cytoplasmic
tail is also correctly localized at the apical microvilli.
The use of an anti-MUC1-CT may constitute an ac-
curate marker for MUC1 because it has not been de-
scribed whether this MUC1 fraction can be liberated
by the cell, although extracellular MUC1 may be se-
creted and released to serum as well as to ascites fluid
(Devine et al. 1993; Linsley et al. 1998; Croce et al.
2001). Release of the ectodomain of MUC1 as a solu-
ble form (MUC1/REP) appears to be the fate of the
majority of MUC1 arriving at the surface of tumor
cells (Julian and Carson 2002). To determine the mo-
lecular mass of the epitopes reactive with MAb CT2,
Western blotting analysis was performed. In agree-
ment with other authors (Schroeder et al. 2001) by
Western blotting assay with MAb CT2, a main band
was detected at about 30 kD, which corresponds to
MUC1-CT. In some samples it was found split into
two bands, which may represent the cytoplasmic and
transmembrane domain, as well as 58 amino acids of
the extracellular region, up to the cleavage site at Ser-
Val-Val-Val (Hilkens et al. 1995; Schroeder et al.
2001).
It is possible that the 60-kD band is an alternative
splice variant of MUC1, such as MUC1/Y (Zrihan–
Licht et al. 1994). Using MAb C595, a characteristic
band with different electrophoretic mobilities at ap-
proximately 200 kD was obtained, corresponding to
the two human alleles of MUC1-VNTR (Price et al.
1990). These bands may correspond to the VNTR se-
quence from the heterodimeric MUC1, MUC1/REP,
or the MUC1/SEC splice form.
In a percentage of subcellular fractions, different
bands of low MW were also found, which may be due
either to different steps of cellular metabolic process-
ing or to generation by sample treatment (Julian and
Carson 2002).
Many carcinoma-associated markers are glyco-
conjugates whose expression undergoes temporal or
spatial regulation. MUC1 mucin is a well-documented
example of such a molecule. In this sense, an anti-
cytoplasmic tail MAb that recognizes the molecule, re-
gardless of the presence of the VNTR sequence, may
be useful to target intracellular MUC1 processing, and
may also be an accurate marker at the membrane
level. It may detect heterodimeric MUC1, MUC1/A,
and MUC1/B variants as well as MUC/Y, MUC/X,
and MUC1/Z isoforms. Alternatively, reactivity with
MAb C595 may be explained by the fact that other
spliced forms, such as MUC1/SEC, may also be ex-
pressed.
Our study indicates that the pattern of expression
of MUC1 CT in breast epithelium may constitute a
better indicator of MUC1 production because it does
not depend on glycosylation. It also shows that the
pattern and extent of MUC1 CT positivity do not vary
according to the histopathological subtype of breast
cancer.
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